• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

With the FDA run­ning out of funds, health­care groups warn that the drug ap­proval process will soon be de­railed

7 years ago
Pharma

FDA fi­nal­izes ac­cel­er­at­ed ap­proval la­bel­ing guid­ance

7 years ago
Pharma

Mi­cro­bio­me, in­flam­ma­tion and mu­ta­tions: US re­searchers win £60M in Can­cer Re­search UK grants to lead 'grand ...

7 years ago
R&D

EC ex­pands ap­proval of Am­gen's Blin­cy­to; FDA gives uniQure green sig­nal to be­gin Hunt­ing­ton's study in hu­mans, ...

7 years ago
News Briefing

No­vo in­fus­es cash in­to 4 biotechs, adding to their ar­se­nal for the su­per­bugs bat­tle to come

7 years ago
Financing

TG Ther­a­peu­tic­s' shares jump as um­bral­is­ib wins FDA's break­through sta­tus

7 years ago
Pharma

Ed­i­tas founder Ka­trine Bosley abrupt­ly steps aside from the helm, just ahead of his­toric CRISPR move

7 years ago
People

Cam­bridge spin­out grabs $23M round to launch a new cam­paign to tack­le pro­tein mis­fold­ing

7 years ago
Financing
Startups

FDA slaps a clin­i­cal hold on mes­sen­ger RNA pro­gram for rare ge­net­ic dis­ease

7 years ago
Pharma

Chi­nese gov­ern­ment probe con­demns Jiankui He as rogue sci­en­tist pur­su­ing 'il­le­gal' work on gene-edit­ed ba­bies

7 years ago
China

Au­rinia eye drug falls short in im­prov­ing tol­er­a­bil­i­ty ver­sus Resta­sis, but beats on ef­fi­ca­cy

7 years ago
R&D

Ab­b­Vie, J&J con­cede a fail­ure for block­buster Im­bru­vi­ca in their PhI­II shot at pan­cre­at­ic can­cer

7 years ago
R&D

Tyme flops on can­cer drug da­ta; Lil­ly IND fil­ing trig­gers $8M pay­ment to part­ner Zymeworks

7 years ago
News Briefing

John Mendlein leaves Mod­er­na for Flag­ship; Paul Sekhri to steer first xeno­trans­plan­ta­tion tri­als as eGe­n­e­sis CEO

7 years ago
Peer Review

Cel­gene's top 20 up­front hits: Just how gen­er­ous was Cel­gene in deal­mak­ing? Let's re­view the records

7 years ago
Pharma

Safe­ty con­cerns lead to a split FDA pan­el vote on Sanofi/Lex­i­con di­a­betes drug

7 years ago
R&D
Pharma

Lil­ly's ap­proved can­cer drug Lartru­vo fails con­fir­ma­to­ry study, set­ting the stage for with­draw­al of reg­u­la­to­ry ...

7 years ago
R&D

Cel­gene inks first deals since Bris­tol-My­ers an­nounced $74B buy­out — bets $80M on im­munome­tab­o­lism

7 years ago
Pharma

Im­munomedics must en­dure an­oth­er de­lay as FDA re­jects can­cer drug cit­ing man­u­fac­tur­ing is­sues

7 years ago
R&D

No­var­tis teams up with Ox­ford re­searchers to crunch big da­ta in­to clin­i­cal in­sights

7 years ago
AI

Scoop: For­ma ax­es dis­cov­ery bi­ol­o­gy team as part of a broad­er re­or­ga­ni­za­tion

7 years ago
R&D
Pharma

With J&J deal to as­sess val­ue of Ap­ple watch in atri­al fib­ril­la­tion, tech gi­ant for­ti­fies its for­ay in­to health­care

7 years ago
Pharma

NIH re­searchers re­port an­i­mal mod­el val­i­da­tion for stem cell-based ap­proach to ad­vanced dry AMD

7 years ago
Discovery

Bay­er ax­ing 665 work­ers at US cam­pus; NASH biotech pumps up share price with an ‘in­ter­im’ snap­shot

7 years ago
News Briefing
First page Previous page 966967968969970971972 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times